Yescarta

Three Pricing Models That Address the High-Cost Gene, Cell Therapies
Three Pricing Models That Address the High-Cost Gene, Cell TherapiesHere are three innovative structures in pricing models to address the high-cost of curative therapies.
Gene Therapy Advances: What Health Execs Should KnowGene therapy is leaving its mark, while payers contemplate payment models, value, and efficacy issues.
Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.